Checkpoint Therapeutics (NASDAQ:CKPT) Announces Earnings Results, Misses Estimates By $0.47 EPS

Checkpoint Therapeutics (NASDAQ:CKPT) issued its quarterly earnings results on Friday. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.47), Zacks reports.

Checkpoint Therapeutics Price Performance

NASDAQ CKPT traded up $0.01 during mid-day trading on Friday, hitting $4.04. The stock had a trading volume of 522,554 shares, compared to its average volume of 1,124,079. The firm’s 50 day moving average is $3.32 and its 200 day moving average is $3.25. The stock has a market capitalization of $197.29 million, a price-to-earnings ratio of -2.20 and a beta of 1.41. Checkpoint Therapeutics has a twelve month low of $1.38 and a twelve month high of $4.50.

Insider Buying and Selling

In other news, CFO William Garrett Gray sold 74,110 shares of the stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $3.67, for a total transaction of $271,983.70. Following the completion of the transaction, the chief financial officer now directly owns 1,458,644 shares in the company, valued at approximately $5,353,223.48. This represents a 4.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO James F. Oliviero III sold 10,331 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $3.15, for a total transaction of $32,542.65. Following the completion of the sale, the chief executive officer now directly owns 3,775,019 shares in the company, valued at $11,891,309.85. This trade represents a 0.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 93,674 shares of company stock worth $336,011. 2.10% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts have recently issued reports on CKPT shares. HC Wainwright reiterated a “neutral” rating and set a $4.10 target price on shares of Checkpoint Therapeutics in a research report on Tuesday, March 11th. Lake Street Capital reaffirmed a “hold” rating and set a $4.10 price objective (down from $7.00) on shares of Checkpoint Therapeutics in a report on Monday, March 10th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $4.80 target price (down previously from $9.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.